Introduction Pozen, founded in 1996, is a pharmaceutical company focused primarily on developing products for the treatment of acute and chronic pain and other pain-related conditions. The company’s main concept is to develop combination pharmaceutical products that combine two active ingredients to enhance patient compliance and improve either efficacy or safety. Scope Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies Highlights Pozen is a pharmaceutical company developing products which can provide improved efficacy, safety or patient convenience in the treatment of acute and chronic pain and pain related conditions. Trexima, the company’s most advanced product candidate, is under FDA review. Trexima is developed by the company in collaboration with GSK. The company has also entered into a collaborative agreement with AstraZeneca. The company generated all of its revenues through license, collaboration, milestone and upfront payments. It did not generate revenues in 2002, and its revenues increased from $4 million to $14 million between 2003 and 2006. The company’s revenues are forecasted to witness an absolute growth of +62 million between 2006 and 2010. Total revenues are estimated to increase at a CAGR of 53% during 2006-2010, from $14 million to $76 million. Royalties on Trexima sales will be the major contributor to the company’s revenue growth during the period. Reasons to Purchase - Access all the important information and analysis on the company in a single report
- Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain
- Gain access to company’s adjusted five year financial data along with key ratios and market capitalization .
TABLE OF CONTENTS
Overview 1
Catalyst 1
Summary 1
Company Structure 6
Company Overview and Key Facts 6
Business Description 7
History 9
Company Financials 11
Stock Market Performance 11
P&L 12
Balance Sheet 15
Cash Flow 15
Business Segment Performance 16
Products & Services 17
Pipeline Products 17
AC Forecast Product Sales 19
Competitors and Strategic Business Relationships 21
Key Competitors 21
Key Suppliers 21
Key Clients 22
Shareholding Structure 23
Strategy 24
Company View 24
Corporate Strategy 26
SWOT Analysis 27
Overview 27
Strengths 28
Weaknesses 29
Opportunities 30
Threats 31
Value Chain Analysis 32
Overview 32
Discovery and Product Development 33
Manufacturing 33
Scorecard 34
Overview 34
Scorecard Analysis 35
Key Employees 36
List of Key Employees 36
Key Employee Biographies 37
Financial and Operational Overview 43
Financial and Operational Overview 43
APPENDIX 46
Ask the analyst 46
Datamonitor consulting 46
Disclaimer 46
TABLE OF FIGURES
Figure 1: Pozen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 13
Figure 2: Pozen - Key Strategic Products Revenues, 2006-2010 ($ Mn) 20
TABLE OF TABLES
Table 1: Pozen - Key Facts 6
Table 2: Pozen - Year-End Share Price and Market Capitalization, 2002-2006 ($) 11
Table 3: Pozen - Key Events Impacting Share Price Performance 11
Table 4: Pozen - Operating Revenue/Cost Analysis, 2002-2006 ($ Mn) 12
Table 5: Pozen - Operating Cost Ratio Analysis, 2002-2006 (% of total revenues) 14
Table 6: Pozen - Balance Sheet, 2002-2006 ($ Mn) 15
Table 7: Pozen - Cash Flow, 2002-2006 ($ Mn) 15
Table 8: Pozen - Revenue Breakdown, 2002-2006 ($ Mn) 16
Table 9: Pozen - In-house Pipeline Products 17
Table 10: Pozen - Collaboration Pipeline 18
Table 11: Pozen- Key Strategic Revenues, 2006-2010 ($ Mn) 19
Table 12: Pozen - Key Competitors 21
Table 13: Pozen - Key Suppliers 21
Table 14: Pozen - Key Clients 22
Table 15: Pozen - Key Shareholders 23
Table 16: Pozen - SWOT Analysis Summary 27
Table 17: Pozen - Value Chain Analysis 32
Table 18: Pozen - Scorecard 34
Table 19: Pozen - Key Employees 36
Table 20: Pozen - Financial and Operational Overview 44 Pages: 46
|
